SNY sanofi.com: שווי פעילות לרווח לפני ריבית, מסים ופחת

Sanofi (SNY) reliability is based on its dominance in immunology and vaccine production. Comparing the EV/EBITDA ratio on GURU.Markets confirms this stability, where 6.04 characterizes this valuation parameter. A steady cash flow from bestsellers supports the business, although pricing pressure and patent expirations create certain risks for future revenues.

This indicator determines the value of a capital-intensive business by accounting for net debt relative to earnings before interest, taxes, depreciation, and amortization. By analyzing the EV/EBITDA ratio of Sanofi (SNY) within a historical context, an investor assesses the real price of the asset without the influence of the financing structure. The metric compares the total enterprise value with its ability to generate cash flow. For Sanofi (SNY), such a valuation is stabilized by the low geopolitical sensitivity of the pharmaceutical sector.